Venus Medtech Acquires InterValve
June 14, 2017—Venus Medtech Inc. announced that it has purchased InterValve, Inc. Beginning in June 2017, Venus Medtech will be responsible for the global production and sales of InterValve's V8 and TAV8 aortic valvuloplasty balloon catheters used in transcatheter aortic valve replacement (TAVR). The V8 and TAV8 have received US Food and Drug Administration and European CE Mark approvals. Venus Medtech is based in Hangzhou, China. InterValve is based in Plymouth, Minnesota.
In April, Venus Medtech announced that its Venus A-valve TAVR system has been approved by the China Food and Drug Administration (CFDA) for sale in China for the treatment of inoperable and high-risk patients. This is China's first homemade TAVR device and the first CFDA-approved TAVR device. In addition to the launch in the Chinese market, Venus Medtech has started its global expansion of the Venus A-valve.